ABSTRACT
Large vessel vasculitis is defined as an inflamatuar disease that mainly affects large arteries, with two main variants, Takayasu arteritis and giant cell arteritis (GCA). GCA may be associated with polymyalgia rheumatica (PMR), a rheumatic inflammatory condition characterized by inflammation of periarticular structures. Fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron emisyon tomography (PET)/computed tomography (CT) is a functional imaging technique frequently used in oncology and plays an important role in the field of inflammatory diseases. The aim of this guideline is to assist nuclear medicine physicians in determining indications, patient preparation, imaging methods, evaluation and reporting stages during the evaluation of patients with suspected or diagnosed large vessel vasculitis and/or PMR with F-18 FDG PET/CT.
Keywords: Large vessel vasculitis, Takayasu arteritis, giant cell arteritis, FDG, PET/CT
REFERENCES
1Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison’s principles of internal medicine. 21st edition. 2022.
2Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1-11.
3Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192.
4Sunderkötter CH, Zelger B, Chen KR, et al. Nomenclature of cutaneous vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2018;70:171-184.
5Koster MJ, Warrington KJ. Classification of large vessel vasculitis: can we separate giant cell arteritis from Takayasu arteritis? Presse Med 2017;46:e205-213.
6Watts RA, Robson J. Introduction, epidemiology and classification of vasculitis. Best Pract Res Clin Rheumatol 2018;32:3-20.
7Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Artritis Rheum 2011;63:633-639.
8Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018;77:636-643.
9Bosch P, Bond M, Dejaco C, et al. Imaging in diagnosis, monitoring, and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations. Ann Rheum Dis 2023;82:124-125.
10Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-1980.
11Slart RHJA, Gladudemans AWJM, Chareonthaitawee P, et al. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging 2018;45:1250-1269.
12Lensen KD, Comans EF, Voskuyl AE, et al. Large-vessel vasculitis: interobserver agreement and diagnostic accuracy of 18F-FDG-PET/CT. Biomed Res Int 2015;2015:914692.
13Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis 2023;2023-224543.
14Jamar F, Buscombe J, Chiti A, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 2013;54:647-658.
15van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 2009;360:1500-1508.
16Parysow O, Mollerach AM, Jager V, et al. Low-dose oral propranolol could reduce brown adipose tissue F-18 FDG uptake in patients undergoing PET scans. Clin Nucl Med 2007;32:351-357.
17Bucerius J, Mani V, Moncrieff C, et al. Optimizing 18F-FDG-PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur J Nucl Med Mol Imaging 2014;41:369-383.
18Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss inn an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005;53:293-297.
19Nielsen BD, Gormsen LC, Hansen IT, et al. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging 2018;45:1119-1128.
20Ponte C, Serafim AS, Monti S, et al. Early variation of ultrasound halo sign with treatment and relation with clinical fetures in patients with giant cell arteritis. Rheumatology (Oxford) 2020;59:3717-3726.
21Stellingwerff MD, Brouwer E, Lensen KJ, et al. Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis: Need for Standardization. Medicine (Baltimore) 2015;94:e1542.
22Lassmann M, Biassoni L, Monsieurs M, Franzius C, Jacobs F. The new EANM paediatric dosage card. EANM Dosimetry and Paediatrics Committees. Eur J Nucl Med Mol Imaging 2007;34:796-798.
23Lassmann M, Biassoni L, Monsieurs M, Franzius C. The new EANM paediatric dosage card: additional notes with respect to F-18. EANM Dosimetry and Paediatrics Committees. Eur J Nucl Med Mol Imaging 2008;35:1666-1668.
24Huet P, Burg S, Le GD, Hyafil F, Buvat I. Variability, and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement. J Nucl Med 2015;56:552-559.
25Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET: a systemic literature review and meta-analysis. Medicine (Baltimore) 2015;94:e622.
26Gheysens O, Jamar F, Glaudemans AWJM, et al. Semi-Quantitative and Quantitative 18F-FDG-PET/CT indices for diagnosing large vessel vasculitis: A critical review. Diagnostics 2012;11:2355.
27Van der Valk FM, Verweij SL, Zwinderman KA, et al. Thresholds for arterial wall inflammamtion quantified by (18)F-FDG PET imaging: Implications for vascular interventional studies. JACC Cardiovasc Imaging 2016;9:1198-1207.
28Yamashita H, Kubota K, Takahashi Y, et al. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. Mod Rheumatol 2012;22:705-711.
29Cimmino MA, Camellino D, Paparo F, et al. High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography. Rheumatology (Oxford) 2013;52:1865-1872.
30Ben-Haim S, Kupzov E, Tamir E, Israel O. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG-PET/CT. J Nucl Med 2004;45:1816-1821.
31Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med 2005;46:1278-1284.
32ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP 2008;38:1-197.
33Sammel AM, Hsiao E, Schembri G, et al. Diagnostic accuracy of positron emission tomography/computed tomography of the head, neck, and the chest for giant cell arteritis: a prospective, double-blind, cross-sectional study. Arthritis Rheumatol 2019;71:1319-1328.
34Thibault T, Durand-Bailloud B, Soudry-Faure A, et al. PET/CT of cranial arteries for a sensitive diagnosis of giant cell arteritis. Rheumatology (Oxford) 2023;62:1568-1575.
35Cheng Y, Lv N, Wang Z, et al. 18F-FDG PET in assessing disease activity in Takayasu arteritis: a meta-analysis. Clin Exp Rheumatol 2013;31:22-27.
36Sammel AM, Hsiao E, Schembri G, et al. Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritis. Int J Rheum Dis 2020;23:582-588.
37Quinn KA, Dashora H, Novakovich E, et al. Use of 18F-Fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis. Rheumatology (Oxford) 2021;60:4384-4389.
38Dashora HR, Rosenblum JS, Quinn KA, et al. Comparing semiquantitative and qualitative methods of vascular 18F-FDG PET activity measurement in large-vessel vasculitis. J Nucl Med 2022;63:280-286.
39Quinn KA, Ahlman MA, Alessi HD, et al. Association of 18F-Fluorodeoxyglucose positron emission tomography and angiographic progression of disease in large-vessel vasculitis. Arthritis Rheumatol 2023;75:98-107.
40Quinn KA, Rosenblum JS, Rimland CA, et al. Imaging acquisition technique influences interpretation of positron emission tomography vascular activity in large-vessel vasculitis. Semin Arthritis Rheum 2020;50:71-76.
